Brexpiprazole intermediate Powder CAS 913614-18-3
Adenine Brexpiprazole
1-Benzo[b]thien-4-ylpiperazine monohydrochloride
CAS No. 913614-18-3
Appearance White powder
Assay ≥99%
Application Brexpiprazole intermediate
Molecular Formula C12H14N2S.HCl
Molecular Weight 254.78
Related products
Brexpiprazole intermediate
CAS 70500-72-0
CAS 22246-18-0
CAS 5118-13-8
CAS 913614-18-3
CAS 66490-33-3
Brexpiprazole is an atypical antipsychotic drug. It is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). The drug received FDA approval on July 13, 2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression. Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
High doses or long-term use of brexpiprazole can cause a serious movement disorder that may not be reversible. Symptoms of this disorder include uncontrollable muscle movements of your lips, tongue, eyes, face, arms, or legs. The longer you take brexpiprazole, the more likely you are to develop a serious movement disorder. The risk of this side effect is higher in women and older adults.